The Horizon 2020 grant will help the Israeli firm commercially develop its noninvasive DNA methylation-based tests for cancer screening and monitoring.
The new Allen Frontiers Group has named four investigators to lead its first cohort of projects, and will launch two new investigative centers at Stanford and Tufts.
The grant is the second in the last six months that the Paul G. Allen Family Foundation has awarded to Chembio for diagnostics development.
The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.
The Collaborative African Genomics Network recently finished its second year of grant funding, hitting many of its milestones, and is already digging into the work for their third year.
CyVerse, the developers believe, better expresses the platform's capacity to provide data management and computation to researchers across multiple scientific disciplines.
The team will employ reverse vaccinology coupled with high-throughput genomics approaches, such as RNA-seq, to deliver the new vaccines within four years.
The European precision medicine project will use Agendia technology to subtype tumors and match patients with targeted therapies.
The consortium will analyze data from patients and mouse models in the first year as part of efforts to find ways of detecting tumors earlier.
The company will use the funds to design and test new 16S amplicon and sequencing approaches for exploring microbiomes.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.